Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

To assess the efficacy and safety of an investigational compound PF-02545920 for the treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing symptoms associated with schizophrenia.

Key facts

Study ID

NCT00570063

Run by

Pfizer

People needed

35

Starts

2007-11-01

Expected to finish

2008-02-18

Last updated by the study team

2017-12-20

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a current diagnosis of schizophrenia.
• Increase in symptoms over the past 2-4 weeks.
• Willing to remain inpatients for the duration of the trial.

You may not qualify if…

• Evidence or history of clinically significant medical problems.
• Females of childbearing potential.
• A primary psychiatric diagnosis other than schizophrenia.
• A diagnosis of substance abuse or dependence in the last 6 months.

Where it is running

• California Clinical Trials Medical Group, Inc. — Glendale, California, United States
• Glendale Adventist Medical Center — Glendale, California, United States
• Telecare-Cresta Loma — Lemon Grove, California, United States
• California Clinical Trials Medical Group — Paramount, California, United States
• LaPaz Geropsychiatric Center — Paramount, California, United States
• California Clinical Trials Medical Group — San Diego, California, United States
• Connecticut Mental Health Center-Yale University, Clinical Neuroscience Research Unit — New Haven, Connecticut, United States
• CRI Worldwide, LLC — Willingboro, New Jersey, United States
• St. Anthony Hospital — Oklahoma City, Oklahoma, United States
• IPS Research Company — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.